Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia

Cancer Letters
A SharmaR M Straubinger

Abstract

Paclitaxel, a recently approved antineoplastic agent, is cleared slowly from the peritoneal cavity after i.p. injection, and therefore appears to be promising for intracavitary therapy of malignancies confined to the peritoneal cavity. However the dose-limiting toxicity of Taxol, the clinical formulation of paclitaxel, was severe abdominal pain, likely caused by the excipients (Cremophor EL and ethanol) that are required to overcome low drug solubility. We tested the hypothesis that a liposome-based formulation could modulate paclitaxel toxicity independent of antitumor activity. The dose-dependence of toxicity and antitumor effect of paclitaxel liposomes was evaluated after i.p. administration against i.p. P388 leukemia. Liposomal paclitaxel showed antitumor activity similar to that of free paclitaxel (as Taxol), but was better tolerated by both healthy and tumor-bearing mice.

References

Sep 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MarkmanM Phillips
Apr 1, 1990·Journal of Microencapsulation·M H BartoliF Puisieux
Jul 11, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R B WeissB Leyland-Jones
Jun 7, 1980·British Medical Journal·D Dye, J Watkins
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyR C Donehower
May 13, 1994·Journal of Chromatography. B, Biomedical Applications·A SharmaR M Straubinger
Jun 1, 1994·Pharmaceutical Research·A Sharma, R M Straubinger
Jan 1, 1993·Journal of Cancer Research and Clinical Oncology·M Markman
Jul 1, 1995·Cancer·A BicherD M Gershenson

❮ Previous
Next ❯

Citations

Mar 28, 1997·International Journal of Cancer. Journal International Du Cancer·A SharmaR J Bernacki
Feb 8, 2013·Angiogenesis·Guido BocciRomano Danesi
Apr 21, 2007·Pharmaceutical Research·Max TsaiJessie L-S Au
Jun 13, 2013·Pharmaceutical Research·Arehalli S ManjappaRayasa S Ramachandra Murthy
Jul 17, 2012·Cancer Letters·Lan Feng, Russell J Mumper
Mar 11, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·O SoepenbergJ Verweij
May 4, 2004·Journal of Colloid and Interface Science·Lingyun Zhao, Si-Shen Feng
Jan 21, 2000·Journal of Controlled Release : Official Journal of the Controlled Release Society·P CrosassoL Cattel
Jan 21, 2000·Journal of Controlled Release : Official Journal of the Controlled Release Society·M CerutiL Cattel
Nov 10, 2000·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·K NishidaJ Nakamura
Jul 17, 1999·Pharmaceutical Science & Technology Today·R Cortesi, C Nastruzzi
Feb 12, 2009·ACS Nano·Ranga ParthaJodie L Conyers
Aug 28, 2012·International Journal of Nanomedicine·Lulu CaiLijuan Chen
Nov 11, 2010·Future Oncology·Ze LuJessie L-S Au
Jul 13, 2004·Drug Development and Industrial Pharmacy·A ManosroiJ Manosroi
Mar 21, 2008·Journal of Pharmaceutical Sciences·Daryl C DrummondDmitri B Kirpotin
Sep 6, 2001·Journal of Pharmaceutical Sciences·R B CampbellR M Straubinger
Sep 20, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Stěpán Koudelka, Jaroslav Turánek
Mar 27, 2010·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·Daquan ChenQineng Ping
Aug 5, 2015·Nature Communications·Jayanta BhattacharyyaAshutosh Chilkoti
Jun 17, 2004·AAPS PharmSci·Gerald J Fetterly, Robert M Straubinger
Dec 26, 2001·Biopharmaceutics & Drug Disposition·G J FetterlyR M Straubinger
Jan 3, 2019·Drug Development and Industrial Pharmacy·Arehalli S Manjappa, Rayasa S Ramachandra Murthy
Sep 21, 2010·Nanotechnology·Shuyan MengCaicun Zhou
Sep 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·William T PhillipsBeth Goins
Nov 7, 2020·International Journal of Pharmaceutics·Pétronille RoyVincent Boudy

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.